Regadenoson

Drug Profile

Regadenoson

Alternative Names: CVT 3146; Lexiscan; Rapiscan

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator CV Therapeutics
  • Developer Astellas Pharma; Gilead Sciences; Rapidscan Pharma Solutions
  • Class Purines; Pyrazoles; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders

Most Recent Events

  • 12 May 2011 GE Healthcare acquires promotion and distribution rights to regadenoson in the UK and Germany
  • 26 Jan 2011 Registered for Coronary disorders (Diagnosis) in European Union (IV)
  • 27 Sep 2010 Adverse events data in patients with asthma and chronic obstructive pulmonary disease released by Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top